Post hoc analysis shows that participants who took 100 mg or 200 mg of lasmitidan had statistically significant increases in the rate of pain relief and freedom from the most bothersome symptom (MBS) (ie, nausea, photophobia, or phonophobia) (P < .001 starting as early as 30 minutes after administration.
Participants who rated themselves as nonresponders, poor responders, or good responder to triptans did not have significant differences in their responses to 200 mg lasmiditan in any measure (freedom from pain at 2 hours, freedom from MBS, or pain relief). Participants who took 100 mg of lasmiditan vs placebo did have statistically significant differences in freedom from pain at 2 hours (odds ratio [OR] 4.5 vs 1.8, P = .056) and MBS freedom (OR 3.2 vs 1.5, P = .042). Risk relative to placebo of experiencing a treatment-emergent adverse event was significantly lower for poor/non responders vs good responders for each lasmiditan dose.
“The ability to quickly stop migraine attacks continues to be an important objective in advancing the acute treatment of this serious disorder,” said Gudarz Davar, MD, vice president, neurology development, Lilly Bio-Medicines. “These new analyses showed that lasmiditan may provide rapid relief from a migraine attack and may be an effective option for people who have tried triptans. The data presented from the lasmiditan phase 3 program included more than 4,000 patients and treatment of over 20,000 migraine attacks. This research represents Lilly's commitment to helping people across the spectrum of the disease.”
The data includes pooled post hoc analyses of the SAMURAI (NCT02439320) and SPARTAN (NCT02605174) trials and was presented at the American Academy of Neurology annual meeting May 4-10, Philadelphia, PA. Lasmiditan selectively targets 5-HT1Freceptors expressed in the trigeminal pathway and is designed for acute treatment without vasoconstrictive activity.
Mark B. Skeen, MD
Daniel S. Reich, MD, PhD
Konstantin Balashov, MD, PhD